Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma

Solange Landreville, Olga A. Agapova, Katie A. Matatall, Zachary T. Kneass, Michael D. Onken, Ryan S. Lee, Anne M. Bowcock, J. William Harbour

Research output: Contribution to journalArticle

134 Citations (Scopus)

Abstract

Purpose: Metastasis is responsible for the death of most cancer patients, yet few therapeutic agents are available which specifically target the molecular events that lead to metastasis. We recently showed that inactivating mutations in the tumor suppressor gene BAP1 are closely associated with loss of melanocytic differentiation in uveal melanoma (UM) and metastasis. The purpose of this study was to identify therapeutic agents that reverse the phenotypic effects of BAP1 loss in UM. Experimental Design: In silico screens were done to identify therapeutic compounds predicted to differentiate UM cells using Gene Set Enrichment Analysis and Connectivity Map databases. Valproic acid (VPA), trichostatin A, LBH-589, and suberoylanilide hydroxamic acid were evaluated for their effects onUM cells using morphologic evaluation, MTS viability assays, bromodeoxyuridine incorporation, flow cytometry, clonogenic assays, gene expression profiling, histone acetylation and ubiquitination assays, and a murine xenograft tumorigenicity model. Results: Histone deacetylase (HDAC) inhibitors induced morphologic differentiation, cell-cycle exit, and a shift to a differentiated, melanocytic gene expression profile in culturedUMcells. VPA inhibited the growth of UM tumors in vivo. Conclusions: These findings suggest that HDAC inhibitors may have therapeutic potential for inducing differentiation and prolonged dormancy of micrometastatic disease in UM.

Original languageEnglish
Pages (from-to)408-416
Number of pages9
JournalClinical Cancer Research
Volume18
Issue number2
DOIs
StatePublished - Jan 15 2012
Externally publishedYes

Fingerprint

Histone Deacetylase Inhibitors
Growth
Valproic Acid
Neoplasm Metastasis
trichostatin A
Ubiquitination
Gene Expression Profiling
Bromodeoxyuridine
Therapeutics
Acetylation
Tumor Suppressor Genes
Transcriptome
Heterografts
Computer Simulation
Histones
Neoplasms
Cell Cycle
Flow Cytometry
Research Design
Uveal melanoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. / Landreville, Solange; Agapova, Olga A.; Matatall, Katie A.; Kneass, Zachary T.; Onken, Michael D.; Lee, Ryan S.; Bowcock, Anne M.; William Harbour, J.

In: Clinical Cancer Research, Vol. 18, No. 2, 15.01.2012, p. 408-416.

Research output: Contribution to journalArticle

Landreville, S, Agapova, OA, Matatall, KA, Kneass, ZT, Onken, MD, Lee, RS, Bowcock, AM & William Harbour, J 2012, 'Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma', Clinical Cancer Research, vol. 18, no. 2, pp. 408-416. https://doi.org/10.1158/1078-0432.CCR-11-0946
Landreville S, Agapova OA, Matatall KA, Kneass ZT, Onken MD, Lee RS et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clinical Cancer Research. 2012 Jan 15;18(2):408-416. https://doi.org/10.1158/1078-0432.CCR-11-0946
Landreville, Solange ; Agapova, Olga A. ; Matatall, Katie A. ; Kneass, Zachary T. ; Onken, Michael D. ; Lee, Ryan S. ; Bowcock, Anne M. ; William Harbour, J. / Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. In: Clinical Cancer Research. 2012 ; Vol. 18, No. 2. pp. 408-416.
@article{968c8505d066426287d2ef6e3bd01a76,
title = "Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma",
abstract = "Purpose: Metastasis is responsible for the death of most cancer patients, yet few therapeutic agents are available which specifically target the molecular events that lead to metastasis. We recently showed that inactivating mutations in the tumor suppressor gene BAP1 are closely associated with loss of melanocytic differentiation in uveal melanoma (UM) and metastasis. The purpose of this study was to identify therapeutic agents that reverse the phenotypic effects of BAP1 loss in UM. Experimental Design: In silico screens were done to identify therapeutic compounds predicted to differentiate UM cells using Gene Set Enrichment Analysis and Connectivity Map databases. Valproic acid (VPA), trichostatin A, LBH-589, and suberoylanilide hydroxamic acid were evaluated for their effects onUM cells using morphologic evaluation, MTS viability assays, bromodeoxyuridine incorporation, flow cytometry, clonogenic assays, gene expression profiling, histone acetylation and ubiquitination assays, and a murine xenograft tumorigenicity model. Results: Histone deacetylase (HDAC) inhibitors induced morphologic differentiation, cell-cycle exit, and a shift to a differentiated, melanocytic gene expression profile in culturedUMcells. VPA inhibited the growth of UM tumors in vivo. Conclusions: These findings suggest that HDAC inhibitors may have therapeutic potential for inducing differentiation and prolonged dormancy of micrometastatic disease in UM.",
author = "Solange Landreville and Agapova, {Olga A.} and Matatall, {Katie A.} and Kneass, {Zachary T.} and Onken, {Michael D.} and Lee, {Ryan S.} and Bowcock, {Anne M.} and {William Harbour}, J.",
year = "2012",
month = "1",
day = "15",
doi = "10.1158/1078-0432.CCR-11-0946",
language = "English",
volume = "18",
pages = "408--416",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma

AU - Landreville, Solange

AU - Agapova, Olga A.

AU - Matatall, Katie A.

AU - Kneass, Zachary T.

AU - Onken, Michael D.

AU - Lee, Ryan S.

AU - Bowcock, Anne M.

AU - William Harbour, J.

PY - 2012/1/15

Y1 - 2012/1/15

N2 - Purpose: Metastasis is responsible for the death of most cancer patients, yet few therapeutic agents are available which specifically target the molecular events that lead to metastasis. We recently showed that inactivating mutations in the tumor suppressor gene BAP1 are closely associated with loss of melanocytic differentiation in uveal melanoma (UM) and metastasis. The purpose of this study was to identify therapeutic agents that reverse the phenotypic effects of BAP1 loss in UM. Experimental Design: In silico screens were done to identify therapeutic compounds predicted to differentiate UM cells using Gene Set Enrichment Analysis and Connectivity Map databases. Valproic acid (VPA), trichostatin A, LBH-589, and suberoylanilide hydroxamic acid were evaluated for their effects onUM cells using morphologic evaluation, MTS viability assays, bromodeoxyuridine incorporation, flow cytometry, clonogenic assays, gene expression profiling, histone acetylation and ubiquitination assays, and a murine xenograft tumorigenicity model. Results: Histone deacetylase (HDAC) inhibitors induced morphologic differentiation, cell-cycle exit, and a shift to a differentiated, melanocytic gene expression profile in culturedUMcells. VPA inhibited the growth of UM tumors in vivo. Conclusions: These findings suggest that HDAC inhibitors may have therapeutic potential for inducing differentiation and prolonged dormancy of micrometastatic disease in UM.

AB - Purpose: Metastasis is responsible for the death of most cancer patients, yet few therapeutic agents are available which specifically target the molecular events that lead to metastasis. We recently showed that inactivating mutations in the tumor suppressor gene BAP1 are closely associated with loss of melanocytic differentiation in uveal melanoma (UM) and metastasis. The purpose of this study was to identify therapeutic agents that reverse the phenotypic effects of BAP1 loss in UM. Experimental Design: In silico screens were done to identify therapeutic compounds predicted to differentiate UM cells using Gene Set Enrichment Analysis and Connectivity Map databases. Valproic acid (VPA), trichostatin A, LBH-589, and suberoylanilide hydroxamic acid were evaluated for their effects onUM cells using morphologic evaluation, MTS viability assays, bromodeoxyuridine incorporation, flow cytometry, clonogenic assays, gene expression profiling, histone acetylation and ubiquitination assays, and a murine xenograft tumorigenicity model. Results: Histone deacetylase (HDAC) inhibitors induced morphologic differentiation, cell-cycle exit, and a shift to a differentiated, melanocytic gene expression profile in culturedUMcells. VPA inhibited the growth of UM tumors in vivo. Conclusions: These findings suggest that HDAC inhibitors may have therapeutic potential for inducing differentiation and prolonged dormancy of micrometastatic disease in UM.

UR - http://www.scopus.com/inward/record.url?scp=84856023489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856023489&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-11-0946

DO - 10.1158/1078-0432.CCR-11-0946

M3 - Article

C2 - 22038994

AN - SCOPUS:84856023489

VL - 18

SP - 408

EP - 416

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -